4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
CG Oncology, Inc. (CGON) operates in the Biotechnology industry and is headquartered in Dallas, United States with about 142 employees. Its market capitalization is roughly $6 billion. In the fiscal year ended 2025-12-31, CGON reported $4M in revenue and ($161M) in net income.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
Interactive charts & full statements → Open the CGON valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $4M | $1M | $0M | $0M | — |
| Gross Profit | ($1M) | $1M | $0M | — | — |
| Operating Income (EBIT) | ($191M) | ($115M) | ($55M) | ($35M) | — |
| Net Income | ($161M) | ($88M) | ($49M) | ($35M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $1M | $2M | $2M | $0M | $0M |
| Gross Profit | ($2M) | ($1M) | $0M | — | $0M |
| Operating Income (EBIT) | ($66M) | ($49M) | ($51M) | ($49M) | ($42M) |
| Net Income | ($60M) | ($41M) | ($44M) | ($41M) | ($34M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $792M | $755M | $199M | $148M | — |
| Total Liabilities | $39M | $21M | $14M | $23M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CGON viewer.
About TickerBase · Data methodology & sources